Galeterone (TOK-001 or VN/124-1) is an experimental drug being developed by Tokai Pharmaceuticals, Inc. for the treatment of prostate cancer. It is both an androgen receptor antagonist and CYP17A1 inhibitor. It is currently being tested in early phase I/II clinical trials for castration resistant prostate cancer.
^Brawer MK (2008). "New treatments for castration-resistant prostate cancer: highlights from the 44th annual meeting of the american society of clinical oncology, may 30-june 3, 2008, chicago, IL". Rev Urol10 (4): 294–6. PMC2615106. PMID19145273.
^"NCT00959959". ClinicalTrials.gov, United States National Institutes of Health. Retrieved 2011-09-25. "ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer"